Heart failure (HF) is a complex and progressive clinical syndrome that significantly impacts morbidity, mortality and quality of life (QoL).1 On a global scale, HF has become an escalating public health concern, affecting more than 64 million individuals in 2017, and this ...

Epicardial adipose tissue (EAT) is a fat collection directly adjacent to the myocardium and coronary vasculature, lacking any separation and sharing the same circulation.1,2 This anatomy enables direct signalling between EAT and the surrounding tissue, positioning EAT as a central ...

Cardiovascular disease (CVD) is one of the major causes of morbidity and mortality throughout the world.1,2 While traditional risk factors are managed intensively, many individuals continue to have considerable residual risk, and emerging factors such as inflammatory mediators are being ...

The 2025 American Heart Association (AHA) Scientific Sessions (7–10 November; New Orleans, LA, USA) offered a comprehensive overview of the evolving landscape of cardiovascular medicine. This year’s research showcased pivotal trials spanning indications, including hypercholesterolemia, hypertrophic cardiomyopathy, amyloidosis, severe hypertriglyceridaemia, hypertension, ...

Despite advancements in mortality rates from cardiovascular disease (CVD) over the last 50 years, it remains the leading cause of death for women and the third leading cause for women aged 18 to 44.1 A 2011 report from the American Heart Association (AHA) starkly ...

The European Society of Cardiology has released a new consensus statement recognising vaccination as a key element of cardiovascular prevention. By reducing infection-triggered complications and events, vaccines provide added protection for vulnerable patients, including those with coronary disease, heart failure, congenital heart disease, transplant recipients, and pregnant women.

July 2025 marked continued progress in cardiovascular innovation, with notable regulatory decisions and clinical trial milestones. Approvals, designations, and data readouts during the month highlight the field’s ongoing shift toward targeted therapies, gene-based interventions, and outcome-driven evidence. These developments reflect growing momentum in addressing complex and underserved cardiovascular conditions.

The EEA’s Environmental Noise in Europe 2025 report confirms that chronic exposure to noise is a major contributor to cardiovascular and metabolic disease, linked to tens of thousands of premature deaths annually. In this expert interview, Prof. Thomas Münzel highlights the biological mechanisms involved, the inadequacy of current noise thresholds, and the urgent need to integrate environmental noise into clinical guidelines, risk assessments, and public health policy.

Cardiovascular medicine stands at a pivotal crossroads—shaped by rapid advances in precision therapies, a deepening understanding of disease mechanisms, and an urgent imperative to address global health disparities. As the burden of cardiovascular disease continues to evolve, so too ...